As discussed above for preclinical data [60], FMT is expected to alter human microbiomes, including the intra-tumoral one, activating the immune system and inducing antitumor responses, with microbiome-dependent CD8+ T cell activation and decreased tumor infiltration by Tregs. The gene discussed is CD8A; the disease is neoplasm.